Tolterodine

DB01036

small molecule approved investigational

Deskripsi

Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

Struktur Molekul 2D

Berat 325.4876
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.9-3.7 hours
Volume Distribusi * 113 ± 26.7 L
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.

Interaksi Makanan

1 Data
  • 1. Take with food.

Interaksi Obat

1694 Data
Aclidinium The risk or severity of adverse effects can be increased when Tolterodine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Tolterodine.
Mirabegron The risk or severity of urinary retention can be increased when Tolterodine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Tolterodine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Tolterodine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Tolterodine.
Tiotropium The risk or severity of adverse effects can be increased when Tolterodine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Tolterodine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Tolterodine is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Tolterodine is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum toxin type A.
Glucagon Tolterodine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Tolterodine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Tolterodine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Tolterodine is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Tolterodine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Tolterodine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Tolterodine is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Morphine.
Hydromorphone The risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone.
Oxycodone The risk or severity of adverse effects can be increased when Tolterodine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Tolterodine is combined with Butorphanol.
Pentazocine The risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.
Nalbuphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Tolterodine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Tolterodine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Tolterodine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Tolterodine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Tolterodine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Tolterodine is combined with Dezocine.
Methadyl acetate The risk or severity of adverse effects can be increased when Tolterodine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Tolterodine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Tolterodine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Tolterodine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydromorphine.
Ketobemidone The risk or severity of adverse effects can be increased when Tolterodine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Tolterodine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Tolterodine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Tolterodine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Tolterodine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Tolterodine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Tolterodine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Tolterodine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Tolterodine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Tolterodine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Tolterodine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Tolterodine is combined with Carfentanil, C-11.
Codeine The risk or severity of adverse effects can be increased when Tolterodine is combined with Codeine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Tolterodine is combined with Tapentadol.
Benzhydrocodone The risk or severity of adverse effects can be increased when Tolterodine is combined with Benzhydrocodone.
Methadone The risk or severity of adverse effects can be increased when Tolterodine is combined with Methadone.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Tolterodine is combined with Dextropropoxyphene.
Levacetylmethadol The risk or severity of adverse effects can be increased when Tolterodine is combined with Levacetylmethadol.
Meperidine The risk or severity of adverse effects can be increased when Tolterodine is combined with Meperidine.
Alfentanil The risk or severity of adverse effects can be increased when Tolterodine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Tolterodine is combined with Fentanyl.
Naloxegol The risk or severity of adverse effects can be increased when Tolterodine is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Tolterodine.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tolterodine.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Tolterodine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tolterodine.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Tolterodine.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Tolterodine.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tolterodine.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Tolterodine.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Tolterodine.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tolterodine.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Tolterodine.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Tolterodine.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Tolterodine.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Tolterodine.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Tolterodine.
Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tolterodine.
Pentolinium The risk or severity of adverse effects can be increased when Tolterodine is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Tolterodine is combined with Trimethaphan.
Diphenidol The risk or severity of adverse effects can be increased when Tolterodine is combined with Diphenidol.
Fenoterol The risk or severity of adverse effects can be increased when Tolterodine is combined with Fenoterol.
Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione The risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione.
Isopropamide The risk or severity of adverse effects can be increased when Tolterodine is combined with Isopropamide.
Mepenzolate The risk or severity of adverse effects can be increased when Tolterodine is combined with Mepenzolate.
Hexocyclium The risk or severity of adverse effects can be increased when Tolterodine is combined with Hexocyclium.
Dimetindene The risk or severity of adverse effects can be increased when Tolterodine is combined with Dimetindene.
Dexetimide The risk or severity of adverse effects can be increased when Tolterodine is combined with Dexetimide.
Chlorphenoxamine The risk or severity of adverse effects can be increased when Tolterodine is combined with Chlorphenoxamine.
Butylscopolamine The risk or severity of adverse effects can be increased when Tolterodine is combined with Butylscopolamine.
Homatropine The risk or severity of adverse effects can be increased when Tolterodine is combined with Homatropine.
Thonzylamine The risk or severity of adverse effects can be increased when Tolterodine is combined with Thonzylamine.
Methscopolamine The risk or severity of adverse effects can be increased when Tolterodine is combined with Methscopolamine.
Oxitropium The risk or severity of adverse effects can be increased when Tolterodine is combined with Oxitropium.
Batefenterol The risk or severity of adverse effects can be increased when Tolterodine is combined with Batefenterol.

Target Protein

Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M5 CHRM5
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M4 CHRM4

Referensi & Sumber

Synthesis reference: Yatendra Kumar, "PROCESS FOR THE PREPARATION OF TOLTERODINE." U.S. Patent US20040249211, issued December 09, 2004.

Contoh Produk & Brand

Produk: 114 • International brands: 1
Produk
  • Ach-tolterodine Tartrate Extended Release
    Capsule, extended release • 2 mg • Oral • Canada • Generic • Approved
  • Ach-tolterodine Tartrate Extended Release
    Capsule, extended release • 4 mg • Oral • Canada • Generic • Approved
  • Apo-tolterodine
    Tablet • 1 mg • Oral • Canada • Generic • Approved
  • Apo-tolterodine
    Tablet • 2 mg • Oral • Canada • Generic • Approved
  • Detrol
    Tablet, film coated • 2 mg/1 • Oral • US • Approved
  • Detrol
    Tablet, film coated • 1 mg/1 • Oral • US • Approved
  • Detrol
    Tablet, film coated • 2 mg/1 • Oral • US • Approved
  • Detrol
    Tablet, film coated • 1 mg/1 • Oral • US • Approved
Menampilkan 8 dari 114 produk.
International Brands
  • Detrusitol

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul